title: Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
abstract: OBJECTIVE
  Neoadjuvant chemotherapy (NAC) generally induces significant changes in the pathologic extent of disease. This potential down-staging challenges the standard indications of adjuvant radiation therapy. We assessed the utility of lymph node irradiation (LNI) in breast cancer (BC) patients with pathologic N0 status (pN0) after NAC and breast-conserving surgery (BCS).
  
  
  METHODS
  Among 1,054 BC patients treated with NAC in our institution between 1990 and 2004, 248 patients with clinical N0 or N1 to N2 lymph node status at diagnosis had pN0 status after NAC and BCS. Cox regression analysis was used to identify factors influencing locoregional recurrence-free survival (LRR-FS), disease-free survival (DFS), and overall survival (OS).
  
  
  RESULTS
  All 248 patients underwent breast irradiation, and 158 patients (63.7%) also received LNI. With a median follow-up of 88 months, the 5-year LRR-FS and OS rates were respectively 89.4% and 88.7% with LNI and 86.2% and 92% without LNI (no significant difference). Survival was poorer among patients who did not have a pathologic complete primary tumor response (hazard ratio, 3.05; 95% confidence interval, 1.17-7.99) and in patients with N1 to N2 clinical status at diagnosis (hazard ratio = 2.24; 95% confidence interval, 1.15-4.36). LNI did not significantly affect survival.
  
  
  CONCLUSIONS
  Relative to combined breast and local lymph node irradiation, isolated breast irradiation does not appear to be associated with a higher risk of locoregional relapse or death among cN0 to cN2 breast cancer patients with pN0 status after NAC. These results need to be confirmed in a prospective study.
authors.affiliation: Department of Radiation Oncology, Centre René Huguenin, Saint-Cloud, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Daveau
authors.forename: Denise
authors.initials: D
authors.lastname: Stevens
authors.forename: Etienne
authors.initials: E
authors.lastname: Brain
authors.forename: Oscar
authors.initials: O
authors.lastname: Berges
authors.forename: Sylviane
authors.initials: S
authors.lastname: Villette
authors.forename: Patricia
authors.initials: P
authors.lastname: Moisson
authors.forename: Miriam
authors.initials: M
authors.lastname: Gardner
authors.forename: Brigitte
authors.initials: B
authors.lastname: De la Lande
authors.forename: Serge
authors.initials: S
authors.lastname: Lasry
authors.forename: Alain
authors.initials: A
authors.lastname: Labib
authors.forename: Romuald
authors.initials: R
authors.lastname: Le Scodan
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology*; D015182:Lymphatic Irradiation / Q000401:mortality; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D012189:Retrospective Studies
chemical_list: D018943:Anthracyclines